Patient-Centered Insights into Psoriasis: A

Comprehensive Analysis of Treatment

Adherence and Quality of Life in Pakistan

1
 GROUP MEMBERS
Faiza Liaqat ~ L1F20PHMD0002
Nida Azmat ~ L1F20PHMD0015
Maryam Akbar ~ L1F19PHMD0159
Umair ~ L1F20PHMD0192
Shayan ~ L1F20PHMD0127
Abu Bakar ~ L1F20PHMD0138
2
 What is Psoriasis?

Psoriasis is a chronic autoimmune skin

disorder that causes rapid skin cell turnover,
leading to red, scaly patches, inflammation, and
discomfort. It affects millions worldwide and
varies in severity, from minor localized patches
to full-body coverage. Psoriasis is not
contagious but significantly impacts physical,
emotional, and social well-being.
3
 Why Do Patient-Centered Aim of the Study
Insights Matter?
Traditional research often focuses on medical This study aims to:
treatments and clinical outcomes, but
understanding patient experiences, challenges, and 1. Analyse the effectiveness of psoriasis
quality of life is equally important. A patient- treatments from a patient perspective.
centered approach helps:
2. Identify factors affecting treatment adherence
 Evaluate the effectiveness of treatments beyond and satisfaction.
clinical results.
3. Assess the psychological and social impact of
 Identify barriers to treatment adherence (e.g., psoriasis on daily life.
cost, accessibility, side effects).
4. Provide insights that can help healthcare
 Assess how psoriasis impacts daily life, mental professionals improve patient care.
health, and social interactions.

 Improve doctor-patient communication,

leading to better treatment plans.

Date Your Footer Here 4

 QUESTIONNAIRE
Patient-Centered Insights into Psoriasis: A Comprehensive Analysis of Treatment
Adherence and Quality of Life in Pakistan

5
Section 1: Demographic Data (SF-36 Adaptation) 6. Residence:
1. Age Group: A) Urban B) Rural
A) 18–25-year C) 36-45 years 7. Duration of Psoriasis:
B) 26-35 years D) 46 years and above E) Age Specific A) Less than 1 year C) 6-10 years
2. Gender: B) 1-5 years D) More than 10
A) Male C) Other years E) Exact Years: _______
B) Female 8. Family History of Psoriasis
3. Marital Status: A) Yes B) No
A) Single C) Divorced C) Not sure

B) Married D) Widowed
4. Educational Level:
A) No formal education C) Secondary education
B) Primary education D) Higher education
5. Employment Status:
A) Employed C) Student
6
B) Unemployed D) Retired
 Section 2: Treatment Questionnaire (Table Format)
Questions Strongly Disagree Agree Strongly
Disagree Agree
1. The treatment led to a rapid
improvement in my skin symptoms:
2. The treatment suppresses flare-ups:
3. I can easily handle my condition with
this treatment:
4. With this treatment, my skin no longer
itches:
5. My skin is no longer painful with this
treatment:
6. I do not need to get up any earlier than
usual because of the treatment:
7. The time expenditure for visits to the
physician/clinic is acceptable:
8. The time expenditure for the daily
therapy is acceptable:
9. I am not late for appointments because
of the time spent on the treatment:
10. I do not need to change my clothes
several times a day because of the
treatment:
11. I feel well-informed about my skin
condition:
12. My doctor has taken enough time to
explain the condition to me:
13. My doctor has given me sufficient
information about the treatment:
14. There was sufficient time for me to
ask questions:
15. I feel that my healthcare provider
sympathizes with my situation:
7
 Section 2: Treatment Questionnaire (Table Format)

16. I have enough information to carry out the treatment as planned at any time: 31. I remember to apply the treatment as prescribed:
17. I have understood how to implement the treatment to ensure I can always easily handle 32. I can afford the cost of the treatment without difficulty:
my condition: 33. I do not experience difficulty in accessing the treatment:
34.The treatment schedule is manageable for me:
18. I am satisfied with the speed at which the treatment takes effect:
19. I am satisfied with the continuous "management" I have of the condition/flare-ups: 35. I do not forget to apply the treatment on time:
20. I am satisfied with the efficacy of the treatment: 36. I feel motivated to continue the treatment:
21. I am satisfied with the tolerability of the treatment: 37. I do not skip the treatment due to its unpleasant effects:
22. The preparation is easy to use: 38. I can easily apply the treatment without assistance:
23. The preparation is easy to apply during travel: 39. The treatment does not interfere with my daily responsibilities:
24. The preparation is easy to dispense: 40. I feel that the treatment has significantly improved my condition:
25. The preparation is easy to apply in extreme temperatures:
41. I am satisfied with the long-term results of the treatment:
26. The preparation is easy to apply in different seasons:
27. The preparation is not messy during use:
42. I would recommend this treatment to others with psoriasis:
28. I am satisfied with the way the treatment fits into my daily schedule: 43. I am confident in managing my condition with this treatment:
29. The preparation does not interfere with my clothes: 44. I feel less anxious about my psoriasis due to this treatment:
30. The preparation does not interfere with my skin's natural texture: 45. The treatment has improved my quality of life:
8
 Section 2: Treatment Questionnaire (Table Format)
46. My physician regularly monitors my progress: 61. I understand the potential side effects of the medication:
62. I have adequate support to manage my condition:
47. Follow-up appointments are scheduled at convenient times:
63. I rarely need additional treatments to manage psoriasis flare-ups:
48. My physician regularly asks for feedback about my treatment: 64. The treatment is worth the cost:
49. I feel my treatment plan is tailored to my needs: 65. I feel confident about continuing the prescribed regimen:
50. I am encouraged to voice concerns about my treatment: 66. The treatment allows me to participate in daily activities without restriction:
67. My treatment is personalized to match my symptoms:
51. I am pleased with the consistency of the treatment's effectiveness: 68. I feel empowered to manage my psoriasis:
52. The treatment has had a noticeable impact on my social confidence: 69. I feel that this treatment plan provides the best option for me:
53. I can easily obtain the medication when I need it:
54.The preparation doesn’t cause discomfort after application:
55. I trust my healthcare provider's expertise in managing psoriasis:
56. I believe the treatment has improved my long-term prognosis:
57. The treatment fits well into my lifestyle:
58. My family supports my treatment regimen:
59. I can ask my physician for alternative options if needed:
60. I believe my treatment experience could benefit others: 9
 Section 3: Quality of Life (DLQI Questions)
Questions Very A A Not
much lot little at
All
1. How itchy, sore, painful, or stinging has your skin
been?

2. How much has your skin interfered with shopping

or home activities?

3. How much has your skin influenced the clothes you

wear?

4. How much has your skin affected social or leisure

activities?

5. How much has your skin made it difficult for you

to do any sport?

6. Has your skin prevented you from working or

studying?

7. If 'No,' how much has your skin been a problem at

work or studying?

8. How much has your skin created problems with

your partner, close friends, or relatives?

9. How much has your skin caused any sexual

difficulties?

10. How much of a problem has the treatment for

your skin been (e.g., making your home messy or
taking up time)?
Section 1: Demographic Data (SF-36 Adaptation)
This section collects basic patient information to understand how different factors influence psoriasis and
treatment responses. It includes:
 Age Group (To see if psoriasis severity or treatment experience varies with age).
 Gender (To analyze differences in treatment effectiveness and psychological impact).
 Marital Status (To assess whether social support affects disease management).
 Educational Level (To determine if education level influences treatment awareness).
 Employment Status (To evaluate how psoriasis affects professional life).
 Residence (Urban/Rural) (To check differences in access to treatment and healthcare).
 Duration of Psoriasis (To analyze how long patients have been dealing with the disease).
 Family History (To check genetic links and inheritance patterns).
Purpose: This section helps identify patterns in patient demographics and how these factors influence disease
management.
Section 2: Treatment Questionnaire
This section focuses on patient experiences with treatment, covering:
 Effectiveness (Does it reduce symptoms, itching, and flare-ups?)
 Convenience (Is the treatment easy to apply, manage, and fit into daily life?)
 Satisfaction (Are patients happy with the results, speed, and overall experience?)
 Doctor-Patient Communication (Has the healthcare provider provided enough
guidance?)
 Affordability & Accessibility (Can patients easily afford and access the treatment?)
Purpose: To evaluate how well current treatments are working and identify barriers to
patient adherence.
Section 3: Quality of Life (DLQI Questions)
This section assesses how psoriasis affects daily life, including:
 Physical Discomfort (Pain, itching, and burning sensations).
 Impact on Activities (Work, shopping, sports, social life).
 Emotional & Social Impact (Self-confidence, relationships, and psychological well-
being).
 Sexual & Personal Life (Effect on intimacy and self-image).
 Treatment Burden (Time, inconvenience, and side effects).
Purpose: To understand how psoriasis affects mental health, social life, and overall
well-being, helping improve future treatment approaches.
14
1. References
Health-Related Quality of Life in Psoriasis: Literature Review. (2024). International Journal of Environmental
Research and Public Health.
Key Objective: This review aimed to evaluate the impact of psoriasis on patients' health-related quality of life
(HRQoL) and to assess the effectiveness of various treatment modalities in improving HRQoL. The study highlighted
the use of both generic (e.g., SF-36) and dermatology-specific (e.g., DLQI) instruments to measure HRQoL,
emphasizing the importance of these tools in understanding the broader effects of psoriasis beyond clinical
symptoms.
2.
Bhosle, M. J., Kulkarni, A., Feldman, S. R., & Balkrishnan, R. (2006). Quality of life in patients with psoriasis. Health
and Quality of Life Outcomes, 4(35).
Key Objective: This study reviewed the impact of psoriasis on patients' quality of life, utilizing instruments such as
the DLQI and SF-36 to measure the extent of impairment. The research underscored the significant negative effect of
psoriasis on both physical and mental health components of quality of life and discussed the role of effective
treatment strategies in mitigating these impacts.

15
3. References
Lizán, L., Gabás-Rivera, C., Belinchón, I., Dilla, T., Huete, T., & Díaz, S. (2019). Patient-reported outcomes assessment tools for use
in psoriasis in Spain: A systematic review. Actas Dermo-Sifiliográficas, 110(10), 844–855.
Key Objective: This systematic review aimed to identify and evaluate patient-reported outcome (PRO) instruments validated for use
in Spanish patients with psoriasis. The study assessed the psychometric properties of various HRQoL questionnaires, including the
DLQI and SF-36, and highlighted their application in capturing the impact of psoriasis on patients' lives.

4.
Low Grade of Satisfaction Related to the Use of Current Systemic Therapies in Pustular Psoriasis: A Cross-Sectional Study. (2023).
Frontiers in Medicine.
Key Objective: This study investigated patient satisfaction with current systemic therapies for pustular psoriasis, assessing
treatment effectiveness, convenience, and overall satisfaction. The research utilized patient-reported outcome measures to evaluate
the impact of treatments on quality of life and highlighted the need for more effective therapeutic options

5.
Trovato, E., Dragotto, M., Capalbo, E., Cartocci, A., Rubegni, P., & Calabrese, L. (2024). Uncovering the differences: How DLQI and
WHO-5 scores vary in moderate-to-severe psoriasis patients treated with tildrakizumab 100 mg vs. 200 mg? Journal of Clinical
Medicine, 13(17), 5240.
Key Objective: This study aimed to evaluate differences between DLQI and WHO-5 scores in adult patients with moderate-to-severe
psoriasis treated with two different dosages of tildrakizumab. The research assessed the impact of treatment on patients' quality of
life and well-being, providing insights into the effectiveness of the therapy.
16
 Analyzing Patient Satisfaction
Objectives of the questionnaire
and Adherence
•To evaluate the effectiveness of different •Ease of incorporating treatment into
psoriasis treatments by assessing symptom daily life.
improvement, flare-up suppression, and treatment
tolerability. •Motivation to continue treatment.
•To analyze patient adherence and satisfaction
with various treatment options, including ease of
•Forgetting/skipping treatment due to
use, accessibility, affordability, and side effects. inconvenience or side effects.

•To assess the impact of psoriasis on patients’ •Doctor-patient communication and trust
quality of life, including daily activities, work, in healthcare provider.
relationships, and psychological well-being.

•To identify common triggers and progression

•Availability of alternative options if
patterns of psoriasis among patients. needed.

•To assess healthcare provider involvement in •Affordability and accessibility of

patient education, treatment monitoring, and treatment.
overall management of the condition.

• To gather insights for improving psoriasis

17
treatment strategies and guiding future
Understanding the Effectiveness of
Psoriasis Treatments
•Questions on different treatment types (topical, oral,
biologics, phototherapy, alternative therapies).

•Treatment effectiveness (e.g., improvement in

symptoms, reduction in flare-ups, impact on daily life).

•Time taken for treatment to show results.

•Side effects experienced.

•Satisfaction with treatment cost and accessibility.

•Ease of use, application, and travel compatibility.

•Doctor’s involvement in treatment monitoring and

explanations.

18
 CONCLUSION

• Psoriasis significantly affects patients' quality of life,

including physical, emotional, and social well-being.

• Patient-centered insights help evaluate treatment

effectiveness beyond clinical outcomes.

• Adherence to treatment is influenced by affordability,

convenience, side effects, and doctor-patient communication.

• Psychological and social impacts, such as stress, anxiety,

and stigma, play a crucial role in disease management.

19
THANK YOU

20